Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
Amgen Inc. announced that the U.S. Food and Drug Administration has asked the company to participate in a meeting of the Reproductive Health Drugs Advisory Committee on Aug. 2009. The RHDAC will review data supporting the Biologics License Application for denosumab, a RANK Ligand inhibitor for which Amgen is seeking approval for prevention and treatment of postmenopausal osteoporosis and prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate or breast cancer. [more...]
|
|
|
